Evonik's Two Clocks: A November Earnings Date and a Takeover That Waits on the Books
Published on 10/22/2026 at 14:40 | Editorial boerse-global.de
Evonik investors are tracking two timelines that run on entirely different schedules. One is fixed and public: the third-quarter 2026 report, due 3 November. The other has no date at all — BASF's courtship, which hinges on access to Evonik's books, the stance of its largest shareholder and a political establishment that has already made its misgivings known.
The distinction matters because the two strands answer different questions. Operational progress says nothing about whether a deal gets done, and deal momentum says nothing about how the chemicals group trades on its own merits.
What the pipeline shows — and what it doesn't
Evonik has kept its product engine running through the uncertainty. It recently unveiled stiffer VESTAKEEP PEEK grades aimed at long-term dental prosthetics, alongside Lypron, an addition to its amino-acid balancing concept for ruminant nutrition. A recycling initiative launched roughly a week ago with Toyotsu Chemiplas and Sanyo Chemical in Japan adds a third strand: the partners intend to convert old polyurethane foam into recycled polyols and amines for new PU products.
Each of these is a concrete activity with a defined target. None comes with a revenue or earnings figure attached. That gap is precisely where investors need discipline — a product announcement is not the same thing as a demonstrated financial contribution.
The shareholder that hasn't blinked
On the deal side, the RAG-Stiftung sits at the center of the puzzle. The foundation holds 44% of Evonik, according to Handelsblatt, giving its posture outsized weight. Its board of trustees met on 9 October and declined to take a position on BASF's approach, pointing instead to bilateral talks between the two companies.
Should investors sell immediately? Or is it worth buying Evonik?
That silence is neither a green light nor a rejection — a nuance that matters for how the stock gets valued. Anyone betting on a takeover is also betting on the judgment of a major holder that has so far kept its cards face down. Whether the foundation would back a sale of its stake is the pivotal variable: a supportive stance could strengthen the case for an agreement, while opposition would dent expectations. Both remain scenarios, not decisions.
Labor has already signaled discomfort. In a letter to works councils at BASF and Evonik dated 9 October, IG BCE chief Michael Vassiliadis and Alexander Bercht questioned a full sale and warned against rushing. The debate, then, is not only about price but about whether — and in what shape — the stake should change hands at all.
The price gap and the due-diligence condition
The financial starting point is BASF's reported willingness to discuss a higher offer once it has seen Evonik's books. Evonik turned down the initial bid of EUR 22.15 per share as too low, according to dpa-AFX sources. A sweeter bid would be an economic incentive — but no proof that the key parties would support a sale.
On the employment question, Reuters reported on 12 October, citing two people close to BASF, that the suitor would honor Evonik's German site and job guarantees in the event of a takeover. That commitment is explicitly conditional on a deal closing; it confirms nothing. Such assurances could soften objections without substituting for shareholder approval or agreement on price.
Politics: two separate facts, not one verdict
North Rhine-Westphalia's economy minister, Mona Neubaur, came out against a BASF takeover of Evonik in the state parliament on 14 October, Handelsblatt reported. On the same day, the Landtag rejected an SPD motion that would have examined a state stake in Evonik.
Those are two distinct facts: a minister's opposition to a takeover, and a parliamentary refusal to probe a state investment. Neither amounts to a corporate decision, and neither settles the fate of the transaction. What they do is lengthen the list of interests investors must weigh alongside the offer price.
Evonik at a turning point? This analysis reveals what investors need to know now.
The risk of front-running the news
Treating BASF's openness to a higher bid as an announcement of one would be a mistake. That openness is tied to seeing the books. If talks stall or the foundation comes out against a sale, the takeover scenario loses its footing — and standalone performance would have to carry the valuation on its own.
For now, with the foundation undecided and a negotiated outcome still conceivable, the deal can be carried as one scenario among several. Should resistance to a sale harden, that scenario deserves a lighter weighting. What would tip the balance is visible decisions and negotiating steps, not the mere prospect of a richer price.
November as the standalone test
The 3 November release is the next confirmed date on the calendar, and the next real opportunity to gauge Evonik's independent trajectory. The dental materials and the Lypron rollout form the operational backdrop; the product statements do not establish any specific earnings contribution.
So two audits proceed side by side. Is the path to a workable takeover agreement improving? And how is Evonik performing economically regardless of it? The RAG-Stiftung's posture remains decisive for the first. For the second, the quarterly report is the next hard data point — and unlike the bid, its date is already circled.
Ad
Evonik Stock: New Analysis - 22 October
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
